Endpoint viability assays were performed using the CellTiter-Glo (Promega) assay according to the manufacturer's protocol. Briefly, cells were seeded at 600 to 800 cells per in 384-well plates or 2,000 cells in 96-well plates and allowed to establish overnight before adding treatments. Cells were treated for 6 to 7 days with compounds, over a range of concentrations, then the assay was terminated and viability assessed using luminescence detection on a Victor X4 plate reader (Perkin Elmer). Luminescence was normalized to DMSO control, and IC50 values were calculated using a sigmoidal dose–response curve fit analysis (Prism software, GraphPad).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.